Oluwatomilade Fatunde

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon et al. · Clinical Cancer Research · 2019 · 184 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

David E. Gerber, Muhammad Shaalan Beg, Farjana Fattah et al. · British Journal of Cancer · 2018 · 97 citations · Full text

Medicine, Oncology, Pharmacology +12

Knowledge and attitudes about hepatitis C virus (<scp>HCV</scp>) infection and its treatment in <scp>HCV</scp> mono‐infected and <scp>HCV</scp>/<scp>HIV</scp> co‐infected adults

Elizabeth H. Chen, Carol S. North, Oluwatomilade Fatunde et al. · Journal of Viral Hepatitis · 2013 · 37 citations

Pharmacy, Health Education, Infectious Diseases +9

HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans

Yuanqing Ma, Allison Joyce, Olivia Brandenburg et al. · Clinical Cancer Research · 2022 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

253 Phase 1 correlative study of ARQ761, a β-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis

David E. Gerber, Yull Arriaga, Muhammad Shaalan Beg et al. · European Journal of Cancer · 2014 · 11 citations

Medicine, Oncology, Pharmacology +9